Información de Charles River Laboratories International Inc, dividendo de Charles River Laboratories International Inc, actividades de los accionistas y más

Más Datos de Charles River Laboratories International Inc Compañía

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Información de la empresa

Código de la empresaCRL

Nombre de la empresaCharles River Laboratories International Inc

Fecha de salida a bolsaJun 23, 2000

Fundada en1994

Director ejecutivoMr James C. Foster

Número de empleados18600

Tipo de seguridadOrdinary Share

Fin del año fiscalJun 23

Dirección251 Ballardvale St

CiudadWILMINGTON

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal01887

Teléfono17812226000

Sitio Webhttps://www.criver.com/

Código de la empresaCRL

Fecha de salida a bolsaJun 23, 2000

Fundada en1994

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr James C. Foster

Chairman of the Board, President, Chief Executive Officer

250.71K

+1.11%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

46.41K

-3.11%

Mr. Robert J. (Bob) Bertolini, CPA

Independent Director

32.80K

--

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

12.03K

-27.10%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

8.38K

-4.21%

Dr. Deborah Turner Kochevar, Ph.D.

Independent Director

7.89K

--

Ms. Shannon M. Parisotto

Corporate Executive Vice President - Discovery and Safety Assessment Management

7.60K

+20.39%

Mr. George E. Massaro, CPA

Independent Director

5.86K

--

Ms. Virginia M. (Gina) Wilson, CPA

Independent Director

3.96K

--

Dr. Nancy C. Andrews, M.D., Ph.D.

Independent Director

3.02K

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr James C. Foster

Chairman of the Board, President, Chief Executive Officer

250.71K

+1.11%

Ms. Birgit Girshick

Chief Operating Officer, Corporate Executive Vice President

46.41K

-3.11%

Mr. Robert J. (Bob) Bertolini, CPA

Independent Director

32.80K

--

Ms. Victoria L. (Vicky) Creamer

Corporate Executive Vice President, Chief People Officer

12.03K

-27.10%

Mr. Joseph W. LaPlume

Corporate Executive Vice President - Corporate Development and Strategy

8.38K

-4.21%

Dr. Deborah Turner Kochevar, Ph.D.

Independent Director

7.89K

--

Desglose de ingresos

Divisa: USDHora de actualización: dom., 6 de abr

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

Por negocioUSD

Nombre

Ganancia

Proporción

DSA

2.45B

60.53%

RMS

829.38M

20.48%

Manufacturing

769.33M

19.00%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

2.24B

55.31%

Europe

1.08B

26.62%

Canada

482.09M

11.90%

Asia Pacific (Region)

196.95M

4.86%

Other

52.82M

1.30%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

DSA

2.45B

60.53%

RMS

829.38M

20.48%

Manufacturing

769.33M

19.00%

Accionista

Hora de actualización: vie., 21 de feb

Estadísticas de accionistas

Tipo

Estadísticas de accionistas

Accionista

Proporción

The Vanguard Group, Inc.

12.49%

Wellington Management Company, LLP

8.30%

BlackRock Institutional Trust Company, N.A.

6.01%

State Street Global Advisors (US)

4.44%

Kayne Anderson Rudnick Investment Management, LLC

3.68%

Other

65.09%

Estadísticas de accionistas

Accionista

Proporción

The Vanguard Group, Inc.

12.49%

Wellington Management Company, LLP

8.30%

BlackRock Institutional Trust Company, N.A.

6.01%

State Street Global Advisors (US)

4.44%

Kayne Anderson Rudnick Investment Management, LLC

3.68%

Other

65.09%

Tipo

Accionista

Proporción

Investment Advisor/Hedge Fund

51.79%

Investment Advisor

38.24%

Hedge Fund

12.50%

Research Firm

4.86%

Pension Fund

1.55%

Bank and Trust

1.37%

Sovereign Wealth Fund

1.16%

Individual Investor

0.91%

Insurance Company

0.07%

Participación institucional

Hora de actualización: lun., 20 de ene

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q1

1384

55.02M

112.00%

-3.67M

2024Q4

1423

54.85M

107.26%

-4.35M

2024Q3

1392

53.78M

105.14%

-5.12M

2024Q2

1399

54.00M

104.84%

-4.00M

2024Q1

1393

53.76M

104.37%

-4.04M

2023Q4

1424

53.56M

104.42%

-4.24M

2023Q3

1446

53.56M

104.42%

-3.98M

2023Q2

1427

52.88M

103.32%

-3.95M

2023Q1

1431

52.72M

103.01%

-2.79M

2022Q4

1416

51.28M

100.65%

-3.46M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

6.13M

12.49%

+58.13K

+0.96%

Dec 31, 2024

Wellington Management Company, LLP

4.08M

8.3%

+335.66K

+8.97%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

2.95M

6.01%

-51.78K

-1.72%

Dec 31, 2024

State Street Global Advisors (US)

2.18M

4.44%

+51.15K

+2.40%

Dec 31, 2024

Kayne Anderson Rudnick Investment Management, LLC

1.81M

3.68%

-134.28K

-6.92%

Dec 31, 2024

Allspring Global Investments, LLC

1.81M

3.68%

+47.22K

+2.68%

Dec 31, 2024

Geode Capital Management, L.L.C.

1.23M

2.51%

+14.79K

+1.21%

Dec 31, 2024

Impactive Capital LP

1.20M

2.45%

+825.95K

+219.44%

Dec 31, 2024

Meritage Group LP

1.07M

2.19%

-111.05K

-9.37%

Dec 31, 2024

Ariel Investments, LLC

1.07M

2.17%

+169.64K

+18.90%

Dec 31, 2024

ETFs relacionados

Hora de actualización: dom., 6 de abr

Nombre

Proporción

First Trust NASDAQ Pharmaceuticals ETF

2.3%

Janus Henderson Small/Mid Cap Growth Alpha ETF

2.1%

Schwab Ariel ESG ETF

1.64%

First Trust Health Care Alphadex Fund

1.55%

VanEck Biotech ETF

1.44%

Invesco S&P 500 Equal Weight Health Care ETF

1.35%

ROBO Global Healthcare Technology & Innovation ETF

1.34%

Franklin Genomic Advancements ETF

1.25%

Hilton Small-MidCap Opportunity ETF

1.07%

Amplify AI Powered Equity ETF

1.02%

First Trust NASDAQ Pharmaceuticals ETF

Proporción2.3%

Janus Henderson Small/Mid Cap Growth Alpha ETF

Proporción2.1%

Schwab Ariel ESG ETF

Proporción1.64%

First Trust Health Care Alphadex Fund

Proporción1.55%

VanEck Biotech ETF

Proporción1.44%

Invesco S&P 500 Equal Weight Health Care ETF

Proporción1.35%

ROBO Global Healthcare Technology & Innovation ETF

Proporción1.34%

Franklin Genomic Advancements ETF

Proporción1.25%

Hilton Small-MidCap Opportunity ETF

Proporción1.07%

Amplify AI Powered Equity ETF

Proporción1.02%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

Charles River Laboratories International Inc

112.945USD

Charles River Laboratories International Inc

112.945

Descripción general

Compañía